Literature DB >> 34072979

A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study.

Julie Lapointe1, Michel Dorval1,2,3, Jocelyne Chiquette1,4, Yann Joly5,6, Jason Robert Guertin1,7, Maude Laberge1,8,9, Jean Gekas4, Johanne Hébert2,10, Marie-Pascale Pomey11,12, Tania Cruz-Marino13, Omar Touhami13, Arnaud Blanchet Saint-Pierre14, Sylvain Gagnon13, Karine Bouchard1, Josée Rhéaume4, Karine Boisvert4, Claire Brousseau4, Lysanne Castonguay4, Sylvain Fortier4, Isabelle Gosselin4, Philippe Lachapelle4, Sabrina Lavoie4, Brigitte Poirier4, Marie-Claude Renaud4, Maria-Gabriela Ruizmangas4, Alexandra Sebastianelli4, Stéphane Roy4, Madeleine Côté4, Marie-Michelle Racine15, Marie-Claude Roy14, Nathalie Côté14, Carmen Brisson14, Nelson Charette14, Valérie Faucher13, Josianne Leblanc13, Marie-Ève Dubeau13, Marie Plante4, Christine Desbiens4, Martin Beaumont4, Jacques Simard1,16, Hermann Nabi1,7.   

Abstract

Medical genetic services are facing an unprecedented demand for counseling and testing for hereditary breast and ovarian cancer (HBOC) in a context of limited resources. To help resolve this issue, a collaborative oncogenetic model was recently developed and implemented at the CHU de Québec-Université Laval; Quebec; Canada. Here, we present the protocol of the C-MOnGene (Collaborative Model in OncoGenetics) study, funded to examine the context in which the model was implemented and document the lessons that can be learned to optimize the delivery of oncogenetic services. Within three years of implementation, the model allowed researchers to double the annual number of patients seen in genetic counseling. The average number of days between genetic counseling and disclosure of test results significantly decreased. Group counseling sessions improved participants' understanding of breast cancer risk and increased knowledge of breast cancer and genetics and a large majority of them reported to be overwhelmingly satisfied with the process. These quality and performance indicators suggest this oncogenetic model offers a flexible, patient-centered and efficient genetic counseling and testing for HBOC. By identifying the critical facilitating factors and barriers, our study will provide an evidence base for organizations interested in transitioning to an oncogenetic model integrated into oncology care; including teams that are not specialized but are trained in genetics.

Entities:  

Keywords:  breast and ovarian cancer; health services delivery; integrated knowledge translation; interdisciplinary research; oncogenetics; prevention; screening; treatment

Year:  2021        PMID: 34072979     DOI: 10.3390/cancers13112729

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  38 in total

1.  BRCA in breast cancer: ESMO Clinical Practice Guidelines.

Authors:  J Balmaña; O Díez; I T Rubio; F Cardoso
Journal:  Ann Oncol       Date:  2011-09       Impact factor: 32.976

2.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

Authors:  Mary B Daly; Robert Pilarski; Matthew B Yurgelun; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Judy E Garber; Michael Goggins; Mollie L Hutton; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Tuya Pal; Holly J Pederson; Gwen Reiser; Kristen Mahoney Shannon; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Mary A Dwyer; Susan D Darlow
Journal:  J Natl Compr Canc Netw       Date:  2020-04       Impact factor: 11.908

Review 3.  The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.

Authors:  Robert Pilarski
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

Review 4.  Highly penetrant hereditary cancer syndromes.

Authors:  Rebecca Nagy; Kevin Sweet; Charis Eng
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

5.  Projecting the Supply and Demand for Certified Genetic Counselors: a Workforce Study.

Authors:  Jennifer M Hoskovec; R L Bennett; M E Carey; J E DaVanzo; M Dougherty; S E Hahn; B S LeRoy; S O'Neal; J G Richardson; C A Wicklund
Journal:  J Genet Couns       Date:  2017-10-20       Impact factor: 2.537

6.  Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Authors:  Timothy R Rebbeck; Noah D Kauff; Susan M Domchek
Journal:  J Natl Cancer Inst       Date:  2009-01-13       Impact factor: 13.506

7.  Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices.

Authors:  Vinay Prasad; John Pa Ioannidis
Journal:  Implement Sci       Date:  2014-01-08       Impact factor: 7.327

8.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Authors:  Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

9.  Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.

Authors:  Bernadette A M Heemskerk-Gerritsen; Cecile T M Brekelmans; Marian B E Menke-Pluymers; Albert N van Geel; Madeleine M A Tilanus-Linthorst; Carina C M Bartels; Murly Tan; Hanne E J Meijers-Heijboer; Jan G M Klijn; Caroline Seynaeve
Journal:  Ann Surg Oncol       Date:  2007-05-31       Impact factor: 5.344

10.  Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.

Authors:  Nina Hallowell; S Wright; D Stirling; C Gourley; O Young; M Porteous
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

View more
  2 in total

1.  Issues associated with a hereditary risk of cancer: Knowledge, attitudes and practices of nurses in oncology settings.

Authors:  Johanne Hébert; Anne-Sophie Bergeron; Anne-Marie Veillette; Karine Bouchard; Hermann Nabi; Michel Dorval
Journal:  Can Oncol Nurs J       Date:  2022-04-01

2. 

Authors:  Johanne Hébert; Anne-Sophie Bergeron; Anne-Marie Veillette; Karine Bouchard; Hermann Nabi; Michel Dorval
Journal:  Can Oncol Nurs J       Date:  2022-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.